Navigation Links
SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
Date:5/13/2008

NATICK, Mass. and BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed two-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety and efficacy of the market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System and reinforce the growing body of positive clinical evidence for the XIENCE(TM) V (PROMUS(TM)) Everolimus-Eluting Coronary Stent System. The results were presented at the 2008 EuroPCR Scientific Program in Barcelona by Gregg W. Stone, M.D., of Columbia University Medical Center and the Cardiovascular Research Foundation in New York, and the Principal Investigator of the SPIRIT III Trial.

The results demonstrated comparable safety and efficacy rates through two years for the XIENCE V (PROMUS) and TAXUS Express Stents. The Ischemia-Driven Target Lesion Revascularization (TLR) rate for the XIENCE V (PROMUS) Stent was 4.3% while the TAXUS Express Stent was 6.9% (p=0.07). The overall Major Adverse Cardiac Event, (MACE a composite endpoint of Cardiac Death, Myocardial Infarction and TLR) rate was 7.3% for the XIENCE V (PROMUS) Stent and 12.8% for the TAXUS Express Stent (p=0.004). In addition, stent thrombosis rates using the ARC (Academic Research Consortium) definite/probable definition were low for the XIENCE V (PROMUS) and the TAXUS Express Stents (1.3% and 1.7%, p=0.77).

"We are very pleased that both the TAXUS Express and PROMUS Stents continue to perform so well in the SPIRIT III trial, adding to the extensive body of clinical evidence reinforcing the excellent safety and efficacy of the market-leading TAXUS Stent and the growing body of positive clinical evidence for the PROMUS Stent at two years,"
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. DATATRAK International Reports First Quarter Results for 2008
8. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
9. Exelixis Announces First Quarter 2008 Financial Results
10. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
11. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... 26, 2011 Masimo (NASDAQ: MASI ) today ... Goldman Sachs 32nd Annual Global Healthcare Conference at Terranea in ... 8:40 a.m. Pacific Time.  A live audiocast of the presentation ... .  A replay of the audiocast will be available following ...
... OTC Markets Group Inc. (OTCQX: OTCM), ... the world,s largest electronic marketplace for broker-dealers to trade ... (TSX.V: VRS; OTCQX: VRSEF), a medical device company ... of cancer, is now trading on the OTC market,s ...
Cached Medicine Technology:Masimo to Present at Goldman Sachs 32nd Annual Global Healthcare Conference 2Verisante Technology Inc. Joins OTCQX 2
(Date:4/24/2014)... thought to be boring and irrelevant, could offer an ... , Researcher Dr Milena Furtado, and her team from ... found the heart cell fibroblast is a close relative ... beating heart. , In research published today in ... fibroblasts are unique cells due to their genetic program, ...
(Date:4/24/2014)... of researchers was the first in the world to ... tumour of the jaw. , Ameloblastoma is an odontogenic ... Ameloblastoma is most often found in the posterior of ... resulting in tissue deficiencies in the jaws as well ... could reduce the need for surgery and the recurrence ...
(Date:4/24/2014)... scientist at the University of York reveals that a ... of the nervous system may also play a pivotal ... research team, led by Dr Will Brackenbury, a Medical ... York, has studied how voltage-gated sodium channels assist in ... in the membranes of excitable cells, such as neurons, ...
(Date:4/23/2014)... State University Spokane have developed a new way ... off behind the wheel. , Their recently patented ... more variable in drowsy driversand offers an affordable ... driver drowsiness detection systems. , Van Dongen"Video-based systems ... is drifting out of its lane are cumbersome ...
(Date:4/23/2014)... - Purdue University researchers have developed a way to ... by using tiny gold particles with tails of synthetic ... agricultural and biological engineering, used gold nanoparticles to target ... BRCA1 messenger RNA splice variants, which can indicate the ... these mRNA splice variants in a cell can be ...
Breaking Medicine News(10 mins):Health News:Boring cells could hold the key to heart disease 2Health News:Breast cancer replicates brain development process 2Health News:WSU innovation improves drowsy driver detection 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... which comes from the foxglove plant, is normally used to ... the heart and treat heart diseases. The chemical nature of ... University of Wisconsin-Madison to make the drug fight against cancer//., ... works by changing the sugars attached to the drug. By ...
... According to a latest study researchers say health professionals ... manage the risks associated with over the counter drugs. ... one of the most common condition that people choose ... of the other commonly treated ailments include heartburn, migraine, ...
... stutent multi-kinase inhibitors against cancer is undergoing phase 3 ... this years ASCO (American Society of Clinical Oncology) conference. ... mechanism of action – known as Multi-kinase inhibitors. These ... and are found to be very effective. This two ...
... two different types of low fat, low cholesterol diets researchers ... diet consisting of lean meats and other low fat foods ... percent. However, those who consumed a diet rich in plant-based ... as well, lowering their LDL levels by about 9.4 percent. ...
... Researchers say Kelp seaweed may be the next food ... findings from an animal study conducted at the University ... the seaweed effectively reduced levels of estradiol, // a ... rats. The rats also experienced a lengthening of their ...
... say an indirect CT venography ( CTV ) could identify ... break free, travel to the lung, and block an artery ... arteries are not visible in a commonly used lung scan, ... presence of these blood clots in the lung. ...
Cached Medicine News:
... for use with GIA DST ... with Titanium Staples)., ,The ... and the SGIA™ Knifeless Stapler ... pediatric and thoracic surgical procedures ...
The Reusable Purse String Clamp is intended for use in the mechanical construction of a purse string suture. The clamp can be used on any part of the gastrointestinal tract except the esophagus....
... Device for use with VALTRAC™ ... Ring)., ,The Purstring™ Device ... and esophageal surgery for the ... and is intended for use ...
... to create an automatic purse-string with ... 45 disposable instrument has application in ... surgery for temporary and permanent purse-string ... disposable instrument has application in intestinal, ...
Medicine Products: